Meeting Information - The company will hold its second extraordinary general meeting of shareholders for 2025 on September 26, 2025, at 14:30 [1] - The meeting will be conducted in a combination of on-site voting and online voting [3] - The record date for shareholders to attend the meeting is September 19, 2025 [4] Voting Details - On-site voting will take place on September 26, 2025, from 14:30, while online voting through the Shenzhen Stock Exchange trading system will be available from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 [2][20] - Shareholders can also vote via the internet from 9:15 to 15:00 on the same day [20] Attendance and Registration - Shareholders or their agents holding shares as of the record date are entitled to attend the meeting [4] - Registration for corporate shareholders requires specific documentation, while individual shareholders must present their ID and proof of shareholding [11][12] Agenda and Proposals - The meeting will review proposals that have been approved by the company's board of directors [9] - One of the proposals requires a special resolution, needing more than two-thirds of the voting rights held by attending shareholders to pass [10] Contact Information - The company has provided contact details for inquiries related to the meeting [18]

关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 大庆华科股份有限公司（以下简称"公司"）定于 2025 年 9 月 26 日（星期五）14:30 召开 2025 年第二次临时股东会（以下简称"本 次股东会"）。会议通知公告（公告编号 2025037）已于 2025 年 9 月 10 日在巨潮资讯网(http://www.cninfo.com.cn) 、《中国证券报》 及《上海证券报》上发布。本次股东会将采用现场投票和网络投票相 结合的方式，现对公司召开本次股东会再次提示公告如下： 一、召开会议的基本情况 证券代码：000985 证券简称：大庆华科 公告编号：2025038 大庆华科股份有限公司 1、股东会届次:2025 年第二次临时股东会。 2、股东会的召集人:公司董事会。 3、会议召开的合法、合规性:本次会议召开符合公司法、证券法 及公司章程等法律、法规、部门规章、规范性文件及业务规则的相关 规定。 4、会议召开时间 （1）现场会议：2025 年 9 月 26 日（星期五）14:30 （2）网络投票 通过深圳证 ...

Group 1 - The company held a performance briefing on September 16, 2025, to discuss its operating results and financial indicators for the first half of 2025 [1] - Daqing Huake primarily engages in the production and sales of petrochemical products, including C9 and C5 series resins and polypropylene powder, with applications in various industrial sectors [1] - In the first half of 2025, the company achieved operating revenue of 959 million yuan, a year-on-year decrease of 0.85%, and a net profit of 9.064 million yuan, a year-on-year increase of 12.99% [1] Group 2 - The company utilizes by-products from ethylene cracking, such as C5 and propylene, for downstream processing, focusing on enhancing and extending its industrial chain [2] - In 2024, the company invested in a 10,800-ton/year butadiene extraction facility, which has been put into operation, and in 2025, it expanded its isoprene hydrogenation facility to 35,000 tons/year [2] - The company aims to strengthen its core competitiveness by collaborating with research institutions and industry leaders, promoting a new model of "industry-university-research-application" cooperation [2] Group 3 - The company previously announced the unsuccessful public listing of its pharmaceutical division's machinery assets, initially priced at 11.8351 million yuan, which was later reduced to 10.6516 million yuan without finding a buyer [3] - The company will continue to seek potential buyers for the assets of its pharmaceutical division following two unsuccessful attempts at public transfer [3]

Core Viewpoint - Daqing Huake's performance in the first half of 2025 shows a slight decline in revenue but an increase in net profit, indicating resilience in a challenging market environment [1][2]. Group 1: Financial Performance - In the first half of 2025, Daqing Huake achieved operating revenue of 959 million yuan, a year-on-year decrease of 0.85% [1]. - The company reported a net profit of 9.064 million yuan, reflecting a year-on-year increase of 12.99% [1]. - The non-recurring net profit was 7.9774 million yuan, which represents a year-on-year decrease of 8.5% [1]. Group 2: Business Operations and Strategy - Daqing Huake primarily engages in the production and sales of petrochemical products, including C5 and C9 series resins and polypropylene powder, with applications in various industrial sectors [1][2]. - The company has invested in expanding its production capabilities, including a 10,800-ton/year butadiene extraction facility and a capacity expansion project for isoprene hydrogenation, now at 35,000 tons/year [2]. - Daqing Huake aims to enhance its C5/C9/propylene industrial chains, focusing on functional, specialized, and high-end applications, while fostering collaborations with research institutions and industry leaders [2]. Group 3: Asset Management - Daqing Huake attempted to sell machinery assets from its pharmaceutical division, initially listed at an assessed value of 11.8351 million yuan, but failed to attract buyers [3]. - The company reduced the asking price to 10.6516 million yuan in a second attempt, which also did not yield any interested parties, leading to the termination of the sale process [3].

Group 1: Investor Relations Activities - The investor relations activity was conducted via an online platform on September 12, 2025, from 15:00 to 16:00 [2] - Key participants included the Chairwoman Zhang Caihong, General Manager Dou Yan, and Financial Director Wu Yunfeng [2] - The company addressed various investor questions during the earnings briefing [2] Group 2: Product Development and R&D - The planning project department has established a dedicated R&D team of 6 personnel, focusing on the "Polypropylene Plant Liquid Catalyst Injection System Process Development" project [2] - The project aims to optimize product structure and enhance product variety through research on polymerization processes and catalyst dosage [2] Group 3: Production Capacity and Utilization - The company is currently operating all major production facilities as planned, with specific capacity utilization rates to be disclosed in regular reports [3][4] - The isobutylene hydrogenation unit has been expanded to a capacity of 35,000 tons/year [5] Group 4: Financial Performance and Growth Strategy - The company aims to enhance its core competitiveness by improving the C5/C9/propylene industrial chain and transitioning products towards functional, specialized, and high-end applications [3] - In 2024, the company invested in a 10,800 tons/year butadiene extraction unit, which has already been put into production [5] - The company is exploring new business areas to mitigate risks associated with its 100% revenue reliance on the chemical business [5] Group 5: Asset Management - The pharmaceutical division's assets were unsuccessfully listed for sale in 2017 and 2025, with plans to seek potential buyers in the future [6]

Group 1 - Daqing Huake Co., Ltd. announced the procurement of petroleum resin packaging bags on September 10, 2025 [1] - The company has made investments in one enterprise and participated in 828 bidding projects [1] - Daqing Huake holds 7 trademark registrations and 11 patents, along with 201 administrative licenses [1] Group 2 - The supplier for the procurement is Liaoning Hongfeng Packaging Co., Ltd. [2] - The procurement is located in Heilongjiang Province [2]

证券日报网讯 9月9日晚间，大庆华科发布公告称，公司拟聘任立信会计师事务所（特殊普通合伙）为 2025年度财务报告及内部控制审计机构。 （文章来源：证券日报） ...

证券日报网讯9月9日晚间，大庆华科（000985）发布公告称，公司于近日召开职工代表大会，经与会职 工代表表决，选举崔凤玲女士为公司第九届董事会职工董事。 ...

大庆华科股份有限公司 董事差旅费管理制度 (2025 年第一次临时股东大会审议通过) 2025年9月9日 大庆华科股份有限公司 董事差旅费管理制度 第一条 为保证大庆华科股份有限公司（以下简称"公司"） 董事、监事积极参与决策，勤勉尽责履职，促进公司持续、稳 健发展，结合公司实际情况，制定本制度。 2、董事外出参加会议或培训，统一安排住宿的，据实报 销住宿费。 第二条 本制度所称差旅费是公司董事出席公司董事会和 股东会以及按《公司章程》行使职权所发生的城市间交通费、 住宿费和伙食补助费等合理费用。 第三条 城市间交通费是指公司董事出差乘坐火车、轮船、 飞机等交通工具所发生的费用。 第五条 住宿费是指公司董事出差期间入住宾馆（包括饭 店、招待所，下同）发生的房租费用，应在规定的上限标准内 凭票据实报销。 第六条 住宿标准如下表： 单位：元/人﹒天 | | | 北京、上海、 | 其他直辖市、省会、经 | 一般地 | | --- | --- | --- | --- | --- | | 序 号 | 职务 | 广州、深圳 | 住宿费上限标准 济特区及沿海开放城市 | 区 | 职务级别 乘坐标准 一般火车 高铁/动车 （ ...

大庆华科股份有限公司 董事、高级管理人员薪酬及绩效考核管理办法 (2025 年第一次临时股东大会审议通过) 2025年9月9日 第四条 公司高级管理人员的薪酬与考核以公司经济效益 及工作目标为基础，根据公司年度经营计划和高级管理人员分 管工作的职责，进行综合考核，根据考核结果确定高级管理人 员的薪酬。 | | | | 第一章 总则 ············· | | --- | | 第二章 管理机构及职责 | | 第三章 薪酬的构成和标准 | | 第四章 薪酬的考核与支付 | | 第五章 约束机制 . | | 第六章 附则 . | 大庆华科股份有限公司 董事、高级管理人员薪酬及绩效考核管理办法 第一章 总则 第一条 为加强大庆华科股份有限公司（以下简称"公司"） 规范治理，建立和完善现代企业激励和约束机制，根据《公司 法》、《上市公司治理准则》等相关法律法规的规定，结合公 司实际，制定本办法。 第二条 适用范围 （一）公司独立董事和外部董事的津贴按股东大会决议通 过的标准发放；内部董事按其在公司的担任职务标准领取薪酬， 不另外领取董事薪酬。 （二）高级管理人员薪酬按本办法执行。 第三条 高级管理人员（以下简称 ...